AstraZeneca to acquire Amolyt | 14-Mar-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 12-Mar-2024 | 11:00 | RNS |
Notice of AGM | 07-Mar-2024 | 11:00 | RNS |
Director/PDMR Shareholding | 06-Mar-2024 | 15:05 | RNS |
Director/PDMR Shareholding | 06-Mar-2024 | 15:00 | RNS |
EMA validates Dato-DXd MAAs for NSQ NSCLC and BC | 04-Mar-2024 | 07:00 | RNS |
Total Voting Rights | 01-Mar-2024 | 15:00 | RNS |
Voydeya recommended for EU approval | 26-Feb-2024 | 07:00 | RNS |
Acquisition of Gracell completed | 22-Feb-2024 | 13:15 | RNS |
Director/PDMR Shareholding | 22-Feb-2024 | 11:00 | RNS |
AstraZeneca prices a $5bn bond offering | 22-Feb-2024 | 07:00 | RNS |
Filing of Form 20-F with SEC | 21-Feb-2024 | 07:00 | RNS |
Annual Financial Report | 20-Feb-2024 | 11:00 | RNS |
AstraZeneca completes acquisition of Icosavax | 19-Feb-2024 | 15:00 | RNS |
Tagrisso plus chemo approved in US for lung cancer | 19-Feb-2024 | 07:10 | RNS |
Currency | UK Pounds |
Share Price | 12,118.00p |
Change Today | 68.00p |
% Change | 0.56 % |
52 Week High | 12,170.00 |
52 Week Low | 9,501.00 |
Volume | 2,180,591 |
Shares Issued | 1,550.24m |
Market Cap | £187,858m |
RiskGrade | 123 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 15 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 1 |
Total | 29 |
Latest | Previous | |
---|---|---|
2nd Interim | 1st Interim | |
Ex-Div | 22-Feb-24 | 10-Aug-23 |
Paid | 25-Mar-24 | 11-Sep-23 |
Amount | 197.00¢ | 93.00¢ |
Time | Volume / Share Price |
16:49 | 1,018 @ 12,118.00p |
16:35 | 460,721 @ 12,118.00p |
16:35 | 100 @ 12,118.00p |
16:35 | 142 @ 12,118.00p |
16:35 | 1,298 @ 12,118.00p |
You are here: research